转移性结直肠癌（mCRC）是一种由各种基因改变引起的异质性疾病。 BRAFV600E突变在约8-12％的患者中发生，并表现为具有侵袭性临床进程和不良预后。在这里，我们回顾了关于BRAFV600E突变体mCRC的当前知识，并提供了一系列关于其临床管理的共识声明。受分子靶向治疗（包括BRAF抑制剂）和免疫检查点抑制剂的出现的影响，BRAFV600E突变体mCRC的治疗格局发生了巨大变化。通过科学文献搜索，找到了BRAFV600E突变体mCRC患者分子检测、治疗和临床监测的可用数据。由欧洲专家小组讨论和制定了共识声明。本手稿提供了针对BRAFV600E突变体mCRC不同临床表现的共识管理指导，并针对治疗顺序选择进行建议。为了指导mCRC患者的适当临床管理和治疗决策，在诊断时必须进行肿瘤组织分析，以确定DNA错配修复/微卫星状态和至少KRAS，NRAS和BRAF基因突变的状态。最后，我们讨论了BRAFV600E突变体mCRC治疗格局的快速演变，并确定了需要改善患者预后的新疗法策略的优先事项。版权所有©2023 Elsevier Ltd.。

Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in approximately 8-12% of patients and is characterised by an aggressive clinical course and poor prognosis. Here we review the current knowledge on BRAFV600E-mutant mCRC and provide a series of consensus statements on its clinical management. The treatment landscape for BRAFV600E-mutant mCRC has changed greatly due to the emergence of molecular targeted therapies (including BRAF inhibitors) and immune checkpoint inhibitors. A scientific literature search identified available data on molecular testing, treatments, and clinical monitoring of patients with BRAFV600E-mutant mCRC. Consensus statements were discussed and developed by a European expert panel. This manuscript provides consensus management guidance for different clinical presentations of BRAFV600E-mutant mCRC and makes recommendations regarding treatment sequencing choices. To guide appropriate clinical management and treatment decisions for mCRC patients, tumour tissue analysis for DNA mismatch repair/microsatellite status and, at a minimum, KRAS, NRAS, and BRAF mutational status is mandatory at the time of diagnosis. Finally, we discuss the rapidly evolving treatment landscape for BRAFV600E-mutant mCRC and define priorities for the development of novel therapeutic strategies that are needed to improve patient outcomes.Copyright © 2023. Published by Elsevier Ltd.